As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our study, we aim to explore sensitivity differences and mechanisms of different molecular subtypes of MIBC to RC48 treatment and develop a strategy for combination therapy against cancer.
View Article and Find Full Text PDFBackground: Due to the low contrast between the vascular lumen and vessel wall, conventional computed tomography (CT) is not an effective method for visualizing the vessel wall. The purpose of this study was to assess the feasibility of vessel wall visualization using contrast-enhanced dual-energy CT (DECT)-derived water-calcium material decomposition (WMD) and subtraction-based dark-blood imaging (DBI). An additional objective of this study was to determine the association of descending aorta wall thickness (WT) and wall area (WA) with cardiovascular disease (CVD) risk factors and to ascertain the potential of DECT-derived WT and WA as image markers for identifying individuals at high risk for future CVD.
View Article and Find Full Text PDFQuality control (QC) in mass spectrometry (MS)-based proteomics is mainly based on data-dependent acquisition (DDA) analysis of standard samples. Here, we collect 2754 files acquired by data independent acquisition (DIA) and paired 2638 DDA files from mouse liver digests using 21 mass spectrometers across nine laboratories over 31 months. Our data demonstrate that DIA-based LC-MS/MS-related consensus QC metrics exhibit higher sensitivity compared to DDA-based QC metrics in detecting changes in LC-MS status.
View Article and Find Full Text PDF